Last edition
News about "CStone Pharmaceuticals "
CStone's CS2009 Secures U.S. FDA IND Clearance for Phase II Trial in Advanced Solid Tumours
CStone Pharmaceuticals has received U.S. FDA IND clearance to begin a Phase II trial of its trispecific antibody CS2009 for advanced solid tumours, advancing its global immunotherapy development programme.
CStone Pharmaceuticals | 16/02/2026 | By News Bureau
CStone Join Hands with SteinCares to Commercialize Sugemalimab in Latin America
As part of this collaboration, SteinCares will be responsible for the regulatory affairs and commercialization activities of sugemalimab in these regions.
CStone Pharmaceuticals | 27/01/2025 | By Aishwarya | 289
CStone Submits Clinical Trial Application in Australia for CS2009
CS2009 features an innovative molecular design that targets PD-1, VEGFA, and CTLA-4 simultaneously, maintaining balanced affinity for PD-1 and CTLA-4.
CStone Pharmaceuticals | 23/12/2024 | By Aishwarya | 216
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy